IPP Bureau
Hikal invests Rs. 500 crore into fine chemicals plant at Panoli
By IPP Bureau - January 10, 2024
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
Tata 1mg and Vitonnix UK get into an exclusive partnership in India
By IPP Bureau - January 10, 2024
Launch innovative vitamin sublingual sprays
Bruker acquires Tornado Spectral Systems to expand biopharma PAT product portfolio
By IPP Bureau - January 10, 2024
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
GSK to acquire Aiolos Bio for US$ 1 billion upfront payment
By IPP Bureau - January 10, 2024
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Merck to acquire Harpoon Therapeutics for US$ 680 million
By IPP Bureau - January 10, 2024
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Cupid receives 16.23 Cr order from Central Medical Services Society
By IPP Bureau - January 09, 2024
The company has secured two orders for male condoms from CMSS worth Rs. 9.65 crores and Rs. 6.58 crores respectively
Caplin Group announces strategic investment of Rs. 700 crore in TN
By IPP Bureau - January 09, 2024
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
Cipla announces JV with Kemwell Biopharma and Manipal Education & Medical Group
By IPP Bureau - January 09, 2024
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Lupin launches second edition of Aptivate Champion Run for Kids
By IPP Bureau - January 09, 2024
Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in Aptivate Champion Run
European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer
By IPP Bureau - January 09, 2024
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Arco Lab acquires an additional 25% stake in Neviton at Rs. 9.22 Cr
By IPP Bureau - January 08, 2024
Arco Lab now holds a 50% stake in Neviton
Cipla Technologies, Pulmatrix agree for development and commercialization of Pulmazole
By IPP Bureau - January 08, 2024
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Mandaviya inaugurates CDSCO Sub Zonal Office and Central Drug Testing Laboratory in Indore
By IPP Bureau - January 08, 2024
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
Pharmaids Pharmaceuticals to acquire Adita Bio Sys in share swap
By IPP Bureau - January 07, 2024
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
Cipla EU to form JV in USA
By IPP Bureau - January 07, 2024
